About this FactMed analysis covering adverse side effect reports of ALMARL patients who developed LYMPHADENOPATHY.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 2 individuals taking ALMARL reported LYMPHADENOPATHY to the FDA. A total of 227 ALMARL drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALMARL and LYMPHADENOPATHY. In doing so, we compare ALMARL with other drugs that cause LYMPHADENOPATHY, to help you evaluate whether or not ALMARL causes LYMPHADENOPATHY. Likewise, this page shows the most highly-reported side effects of ALMARL, so you can see if LYMPHADENOPATHY ranks among ALMARL's most well-known side effects.
Summary Statistics
Reports of ALMARL causing LYMPHADENOPATHY: 2
Reports of any side effect of ALMARL : 227
Percentage of ALMARL patients where LYMPHADENOPATHY is a reported side effect: 0.8811%

FDA reports of any drug causing LYMPHADENOPATHY : 13325
Average percentage for all medicated patients where LYMPHADENOPATHY is reported as a complication: 0.0835%

Physician opinion on ALMARL as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALMARL:
HYPERTENSION ( 76 patients )
PARKINSON'S DISEASE ( 8 patients )
ESSENTIAL TREMOR ( 6 patients )
ATRIAL FIBRILLATION ( 4 patients )
SCHIZOPHRENIA ( 2 patients )
TREMOR ( 2 patients )
ANGINA PECTORIS ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
PALPITATIONS ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
TACHYCARDIA ( 2 patients )
HYPERTROPHY ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with LYMPHADENOPATHY:

ZOMETA (1553 patients)
FOSAMAX (1454 patients)
HUMIRA (1154 patients)
AREDIA (925 patients)
ASPIRIN (921 patients)
METHOTREXATE (818 patients)
ENBREL (762 patients)
PREDNISONE (707 patients)
LAMICTAL (639 patients)
REMICADE (622 patients)
VIOXX (536 patients)
NEXIUM (519 patients)
GOLIMUMAB (501 patients)
PREDNISOLONE (498 patients)
LIPITOR (490 patients)
FOLIC ACID (478 patients)
AMBIEN (475 patients)
IBUPROFEN (475 patients)
SYNTHROID (461 patients)
NEURONTIN (452 patients)
LASIX (438 patients)
VICODIN (415 patients)
LEVAQUIN (408 patients)
ACETAMINOPHEN (404 patients)
PROTONIX (402 patients)
DEXAMETHASONE (381 patients)
OMEPRAZOLE (376 patients)
CELEBREX (370 patients)
ATIVAN (370 patients)
PRILOSEC (369 patients)
ACCUTANE (367 patients)
ALBUTEROL (365 patients)
COUMADIN (355 patients)
OXYCONTIN (354 patients)
LISINOPRIL (342 patients)
ZOFRAN (340 patients)
ALLOPURINOL (339 patients)
PREVACID (328 patients)
XANAX (327 patients)
PERCOCET (327 patients)
TEGRETOL (323 patients)
AMOXICILLIN (323 patients)
DECADRON (321 patients)
CYCLOPHOSPHAMIDE (317 patients)
HYDROCHLOROTHIAZIDE (313 patients)
PREDNISONE TAB (306 patients)
POTASSIUM CHLORIDE (297 patients)
MULTI-VITAMINS (288 patients)
LEVOTHYROXINE SODIUM (283 patients)
MORPHINE (279 patients)
LAMIVUDINE (277 patients)
FUROSEMIDE (275 patients)
LYRICA (273 patients)
DILAUDID (265 patients)
LORAZEPAM (264 patients)
ARANESP (261 patients)
CALCIUM (258 patients)
KETEK (257 patients)
ADVAIR DISKUS 100/50 (253 patients)
PAXIL (253 patients)
CYCLOSPORINE (251 patients)
TOPROL-XL (249 patients)
NORVASC (249 patients)
REVLIMID (241 patients)
ATENOLOL (241 patients)
ZOLOFT (239 patients)
CHEMOTHERAPEUTICS NOS (238 patients)
VITAMIN D (237 patients)
PLAVIX (235 patients)
EFFEXOR (235 patients)
GABAPENTIN (234 patients)
AUGMENTIN '125' (233 patients)
PREMARIN (228 patients)
KLONOPIN (226 patients)
MS CONTIN (224 patients)
OXYCODONE HCL (222 patients)
ELIDEL (219 patients)
ZOCOR (218 patients)
LEXAPRO (217 patients)
SINGULAIR (217 patients)
AVELOX (217 patients)
ADRIAMYCIN PFS (216 patients)
CELEXA (216 patients)
LORTAB (216 patients)
FEMARA (215 patients)
TAMOXIFEN CITRATE (215 patients)
CIPROFLOXACIN (212 patients)
ARIMIDEX (211 patients)
SIMVASTATIN (211 patients)
XELODA (210 patients)
RADIATION THERAPY (206 patients)
TAXOTERE (204 patients)
ZYRTEC (203 patients)
FASLODEX (201 patients)
SEROQUEL (197 patients)
CEPHALEXIN (195 patients)
BACTRIM (193 patients)
WELLBUTRIN (192 patients)
FENTANYL (191 patients)
FLUCONAZOLE (190 patients)
ZITHROMAX (190 patients)
AVONEX (189 patients)
DEPAKENE (188 patients)
CLINDAMYCIN (184 patients)
WARFARIN SODIUM (183 patients)
COMPAZINE (183 patients)
FLEXERIL (181 patients)
THALIDOMIDE (181 patients)
TAXOL (180 patients)
VINCRISTINE (179 patients)
MORPHINE SULFATE (177 patients)
PROZAC (175 patients)
COLACE (172 patients)
DIFLUCAN (171 patients)
DURAGESIC-100 (170 patients)
DIGOXIN (169 patients)
ALLEGRA (168 patients)
VANCOMYCIN (168 patients)
FAMOTIDINE (166 patients)
LOVENOX (165 patients)
CYMBALTA (165 patients)
CYTOXAN (165 patients)
TACROLIMUS (164 patients)
KEFLEX (163 patients)
ACTONEL (162 patients)
HYDROCORTISONE (161 patients)
NEULASTA (160 patients)
NITROGLYCERIN (160 patients)
ALPRAZOLAM (160 patients)
CALCIUM CARBONATE (160 patients)
SULFASALAZINE (160 patients)
TYLENOL (160 patients)
METOPROLOL TARTRATE (159 patients)
DIAZEPAM (158 patients)
AVASTIN (157 patients)
VALTREX (156 patients)
RIBAVIRIN (155 patients)
ZIDOVUDINE (155 patients)
DOXYCYCLINE (154 patients)
TYSABRI (154 patients)
METHYLPREDNISOLONE (153 patients)
ZOLPIDEM (152 patients)
FLOMAX (152 patients)
FORTEO (151 patients)
ZANTAC (150 patients)
CARBAMAZEPINE (149 patients)
CIPRO (148 patients)
FLONASE (146 patients)
MOTRIN (146 patients)
BENADRYL (146 patients)
GEMZAR (145 patients)
NEUPOGEN (144 patients)
CLONAZEPAM (143 patients)
METFORMIN HCL (142 patients)
PEGASYS (142 patients)
ACYCLOVIR (142 patients)
RANITIDINE (142 patients)
PROCHLORPERAZINE (141 patients)
CRESTOR (141 patients)
CLONIDINE (139 patients)
MYCOPHENOLATE MOFETIL (139 patients)
NYSTATIN (139 patients)
ALENDRONATE SODIUM (137 patients)
VITAMIN B-12 (137 patients)
ETOPOSIDE (136 patients)
FERROUS SULFATE TAB (136 patients)
METRONIDAZOLE (135 patients)
VITAMIN E (135 patients)
CHLORHEXIDINE GLUCONATE (135 patients)
DIOVAN (134 patients)
SPIRIVA (132 patients)
CARBOPLATIN (132 patients)
ATARAX (131 patients)
TRAZODONE HCL (131 patients)
INSULIN (130 patients)
ASCORBIC ACID (129 patients)
PROMETHAZINE (129 patients)
CHANTIX (129 patients)
TYLENOL-500 (128 patients)
CLARITIN (128 patients)
GLEEVEC (127 patients)
DEPAKOTE (126 patients)
ROCEPHIN (126 patients)
LAMOTRIGINE (126 patients)
XOLAIR (125 patients)
ELAVIL (124 patients)
PEPCID (123 patients)
REGLAN (123 patients)
AZATHIOPRINE (123 patients)
FLUOROURACIL (123 patients)
LUPRON (122 patients)
AROMASIN (121 patients)
AMITRIPTYLINE HCL (121 patients)
OXYCODONE (121 patients)
HERCEPTIN (120 patients)
LANSOPRAZOLE (120 patients)
AZITHROMYCIN (118 patients)
VALIUM (117 patients)
MULTI-VITAMIN (117 patients)
ONDANSETRON (116 patients)
INFLUENZA VACCINE (116 patients)
PERIDEX (116 patients)
LANTUS (115 patients)
VELCADE (115 patients)
BONIVA (115 patients)
ACIPHEX (113 patients)
KALETRA (113 patients)
AMLODIPINE (112 patients)
REBIF (111 patients)
HYDROCODONE (110 patients)
Most common side effects for patients taking ALMARL:
DEPRESSED LEVEL OF CONSCIOUSNESS (20 patients)
HALLUCINATION (15 patients)
FALL (13 patients)
HYPOGLYCAEMIA (13 patients)
PYREXIA (12 patients)
TREMOR (12 patients)
DIARRHOEA (11 patients)
HEPATIC FUNCTION ABNORMAL (11 patients)
PNEUMONIA (10 patients)
DYSARTHRIA (10 patients)
BLOOD CREATINE PHOSPHOKINASE INCREASED (9 patients)
RENAL FAILURE ACUTE (9 patients)
LIVER DISORDER (9 patients)
CEREBRAL INFARCTION (8 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (8 patients)
DRUG INEFFECTIVE (8 patients)
RENAL IMPAIRMENT (8 patients)
HYPONATRAEMIA (8 patients)
INTERSTITIAL LUNG DISEASE (8 patients)
JAUNDICE (8 patients)
OEDEMA PERIPHERAL (8 patients)
CONDITION AGGRAVATED (7 patients)
DELIRIUM (7 patients)
DYSPHAGIA (7 patients)
DYSPNOEA (7 patients)
HYPOAESTHESIA (7 patients)
RHABDOMYOLYSIS (7 patients)
VOMITING (6 patients)
DELUSION (6 patients)
RESPIRATORY FAILURE (6 patients)
DYSKINESIA (6 patients)
SOMNOLENCE (6 patients)
HEPATIC NEOPLASM MALIGNANT (6 patients)
HYPERGLYCAEMIA (6 patients)
HYPOKALAEMIA (6 patients)
MOVEMENT DISORDER (6 patients)
MUSCULAR WEAKNESS (6 patients)
WHITE BLOOD CELL COUNT INCREASED (5 patients)
BLADDER CANCER (5 patients)
BLOOD ANTIDIURETIC HORMONE INCREASED (5 patients)
RESTLESSNESS (5 patients)
BLOOD OSMOLARITY DECREASED (5 patients)
PLEURAL EFFUSION (5 patients)
C-REACTIVE PROTEIN INCREASED (5 patients)
CONVULSION (5 patients)
RENAL DISORDER (5 patients)
VITH NERVE PARALYSIS (5 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (5 patients)
INTESTINAL OBSTRUCTION (5 patients)
SEPSIS (5 patients)
ROAD TRAFFIC ACCIDENT (5 patients)
MUSCULOSKELETAL PAIN (5 patients)
NAUSEA (5 patients)
ANOREXIA (4 patients)
ATELECTASIS (4 patients)
ATRIAL FIBRILLATION (4 patients)
ATRIOVENTRICULAR BLOCK (4 patients)
BLOOD CREATININE INCREASED (4 patients)
BRADYCARDIA (4 patients)
CARDIAC FAILURE (4 patients)
CONSTIPATION (4 patients)
DECREASED APPETITE (4 patients)
DEHYDRATION (4 patients)
DIZZINESS (4 patients)
PLATELET COUNT DECREASED (4 patients)
PAIN (4 patients)
HYPERTENSION (4 patients)
HYPOTHYROIDISM (4 patients)
ILEUS (4 patients)
METABOLIC ACIDOSIS (4 patients)
SMALL INTESTINE CARCINOMA (4 patients)
URINE OSMOLARITY INCREASED (4 patients)
ABASIA (3 patients)
AGGRESSION (3 patients)
PRURITUS (3 patients)
ANAEMIA (3 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (3 patients)
WHITE BLOOD CELL COUNT DECREASED (3 patients)
ASTHMA (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
RENAL FAILURE (3 patients)
BLOOD PRESSURE DECREASED (3 patients)
BLOOD PRESSURE INCREASED (3 patients)
VASCULITIS (3 patients)
CAROTID ARTERY STENOSIS (3 patients)
THERAPEUTIC AGENT TOXICITY (3 patients)
CHILLS (3 patients)
CHROMATURIA (3 patients)
PETECHIAE (3 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (3 patients)
PORIOMANIA (3 patients)
RENAL ARTERY STENOSIS (3 patients)
PANCYTOPENIA (3 patients)
DRUG ERUPTION (3 patients)
SUDDEN ONSET OF SLEEP (3 patients)
DRUG WITHDRAWAL SYNDROME (3 patients)
VERTIGO (3 patients)
EPILEPSY (3 patients)
FACE OEDEMA (3 patients)
VOLVULUS (3 patients)
GENERALISED OEDEMA (3 patients)
GINGIVAL BLEEDING (3 patients)
HAEMORRHAGE SUBCUTANEOUS (3 patients)
HALLUCINATION, VISUAL (3 patients)
PSYCHIATRIC SYMPTOM (3 patients)
HEART RATE DECREASED (3 patients)
HELICOBACTER TEST POSITIVE (3 patients)
HEPATITIS FULMINANT (3 patients)
HYPERKALAEMIA (3 patients)
HYPOTENSION (3 patients)
IDIOPATHIC THROMBOCYTOPENIC PURPURA (3 patients)
LOSS OF CONSCIOUSNESS (3 patients)
SENSORY DISTURBANCE (3 patients)
LYMPHOMA (3 patients)
MALAISE (3 patients)
MARKEDLY REDUCED DIETARY INTAKE (3 patients)
RENAL TUBULAR DISORDER (3 patients)
NEOPLASM MALIGNANT (3 patients)
SINUS ARREST (3 patients)
ABDOMINAL DISCOMFORT (2 patients)
ABDOMINAL PAIN (2 patients)
ACUTE MYELOID LEUKAEMIA (2 patients)
STOMACH MASS (2 patients)
PERSONALITY CHANGE (2 patients)
AGITATION (2 patients)
ALTERED STATE OF CONSCIOUSNESS (2 patients)
ANAPHYLACTOID REACTION (2 patients)
ANGER (2 patients)
PRODUCTIVE COUGH (2 patients)
RENAL CYST (2 patients)
APHASIA (2 patients)
ASTHENIA (2 patients)
ATRIOVENTRICULAR BLOCK COMPLETE (2 patients)
THIRST (2 patients)
PROSTATE CANCER (2 patients)
BLOOD AMYLASE INCREASED (2 patients)
BLOOD UREA INCREASED (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
SPEECH DISORDER (2 patients)
TUMOUR LYSIS SYNDROME (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CHEST X-RAY ABNORMAL (2 patients)
COLON CANCER (2 patients)
COMA HEPATIC (2 patients)
COMPLETED SUICIDE (2 patients)
CONTUSION (2 patients)
PERFORMANCE STATUS DECREASED (2 patients)
DEFAECATION URGENCY (2 patients)
DEMENTIA ALZHEIMER'S TYPE (2 patients)
RASH PRURITIC (2 patients)
DIABETIC KETOACIDOSIS (2 patients)
DRUG INTERACTION (2 patients)
DRUG LEVEL INCREASED (2 patients)
DYSPEPSIA (2 patients)
DYSSTASIA (2 patients)
ELECTROCARDIOGRAM QT PROLONGED (2 patients)
STEVENS-JOHNSON SYNDROME (2 patients)
EPULIS (2 patients)
EXTRAOCULAR MUSCLE PARESIS (2 patients)
FACIAL PARESIS (2 patients)
FEAR (2 patients)
FEBRILE NEUTROPENIA (2 patients)
FEMORAL NECK FRACTURE (2 patients)
FOOT FRACTURE (2 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (2 patients)
GANGRENE (2 patients)
GASTRIC ULCER HAEMORRHAGE (2 patients)
GINGIVAL HYPERTROPHY (2 patients)
GLOSSOPTOSIS (2 patients)
PLEURISY (2 patients)
PHRENIC NERVE PARALYSIS (2 patients)
HAEMATEMESIS (2 patients)
HAEMATURIA (2 patients)
HAEMOGLOBIN DECREASED (2 patients)
POLLAKIURIA (2 patients)
ORAL INTAKE REDUCED (2 patients)
HEPATIC CYST (2 patients)
HEPATIC ENCEPHALOPATHY (2 patients)
HEPATITIS (2 patients)
HYPERREFLEXIA (2 patients)
HYPERTONIA (2 patients)
HYPERURICAEMIA (2 patients)
RASH PAPULAR (2 patients)
INITIAL INSOMNIA (2 patients)
RETINAL OEDEMA (2 patients)
INTESTINAL FUNCTIONAL DISORDER (2 patients)
RESPIRATION ABNORMAL (2 patients)
IRRITABILITY (2 patients)
RIB FRACTURE (2 patients)
LEG AMPUTATION (2 patients)
LYMPHADENOPATHY (2 patients)
METABOLIC ALKALOSIS (2 patients)
ORAL HERPES (2 patients)
TAKAYASU'S ARTERITIS (2 patients)
MOUTH HAEMORRHAGE (2 patients)
UNRESPONSIVE TO STIMULI (2 patients)
TOXIC SKIN ERUPTION (2 patients)
NEPHROLITHIASIS (2 patients)
SUICIDE ATTEMPT (2 patients)
VENTRICULAR FIBRILLATION (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
UPPER RESPIRATORY TRACT INFECTION (2 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (2 patients)
SHOCK HAEMORRHAGIC (2 patients)
ABDOMEN CRUSHING (1 patients)
CARDIAC FAILURE CONGESTIVE (1 patients)
EOSINOPHILIC PNEUMONIA ACUTE (1 patients)
ESSENTIAL TREMOR (1 patients)
WRONG TECHNIQUE IN DRUG USAGE PROCESS (1 patients)
FUNGAL INFECTION (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALMARL


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about LYMPHADENOPATHY and ALMARL, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALMARL, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALMARL. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALMARL experts. If you are a healthcare provider experienced in prescribing ALMARL, please register here.

Your online appointment book for Gladwin Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use